Janus Henderson Group PLC Sells 82,283 Shares of STAAR Surgical Company $STAA

Key Points

• Janus Henderson reduced its STAAR Surgical stake by 38.7%, selling 82,283 shares during the first quarter and retaining 130,404 shares worth approximately $2.44 million. Institutional investors collectively own 96.7% of the company.
• STAAR Surgical reported quarterly EPS of $0.10, exceeding the $0.05 consensus estimate, while revenue reached $93.52 million and rose 119.6% year over year.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $26.94; targets range from $20 to $40.

Janus Henderson Group PLC decreased its position in STAAR Surgical Company (NASDAQ:STAA - Free Report) by 38.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 130,404 shares of the medical instruments supplier's stock after selling 82,283 shares during the period. Janus Henderson Group PLC owned about 0.26% of STAAR Surgical worth $2,441,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its position in shares of STAAR Surgical by 2,605.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 1,016 shares during the last quarter. Ascentis Independent Advisors purchased a new stake in STAAR Surgical during the first quarter valued at about $77,000. Tower Research Capital LLC TRC boosted its position in STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 4,673 shares during the period. Russell Investments Group Ltd. boosted its position in STAAR Surgical by 9,928.9% during the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier's stock worth $121,000 after purchasing an additional 4,468 shares during the period. Finally, Fifth Third Bancorp increased its stake in shares of STAAR Surgical by 2,867.1% in the first quarter. Fifth Third Bancorp now owns 11,008 shares of the medical instruments supplier's stock worth $206,000 after purchasing an additional 10,637 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Trading Up 4.7%

Shares of STAA stock opened at $24.21 on Friday. The company has a market capitalization of $1.21 billion, a PE ratio of -56.30 and a beta of 1.26. STAAR Surgical Company has a 52-week low of $15.59 and a 52-week high of $35.87. The business's fifty day moving average is $27.19 and its 200 day moving average is $23.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.05. The business had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company's quarterly revenue was up 119.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.10) EPS. On average, equities research analysts anticipate that STAAR Surgical Company will post 0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on STAA shares. Stifel Nicolaus upped their price target on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a "hold" rating in a research note on Thursday, May 14th. Canaccord Genuity Group raised their price target on STAAR Surgical from $27.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, May 14th. Wells Fargo & Company boosted their price objective on STAAR Surgical from $16.00 to $25.00 and gave the company an "equal weight" rating in a research note on Friday, May 15th. UBS Group assumed coverage on STAAR Surgical in a research note on Tuesday, July 28th. They issued a "sell" rating and a $20.00 target price for the company. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 price target on shares of STAAR Surgical in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $26.94.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source